Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study

Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study

Lenalidomide with dexamethasone (Len/Dex) is considered to be an effective and well-tolerated regimen to treat multiple myeloma (MM) patients relapsing after bortezomib induction therapy. With the increase in novel agents targeting refractory and relapsed MM, the identification of clinical or labora...

Full description

Bibliographic Details
Main Authors: Tran-Der Tan, Ying-Chung Hong, Sin-Syue Li, Jui-Ting Yu, Yung-Chuan Sung, Po-Nan Wang, Chieh-Lin Jerry Teng
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Chinese Journal of Physiology
Subjects:
cytogenetics
lenalidomide
multiple myeloma
relapse
treatment response
Online Access:http://www.cjphysiology.org/article.asp?issn=0304-4920;year=2020;volume=63;issue=5;spage=211;epage=217;aulast=Tan

Internet

http://www.cjphysiology.org/article.asp?issn=0304-4920;year=2020;volume=63;issue=5;spage=211;epage=217;aulast=Tan

Similar Items